Venetoclax, an oral inhibitor targeting BCL2, has shown encouraging clinical activity in patients with plasma cell neoplasms harboring t(11;14), characterized by high levels of BCL2 expression [12]. This evidence concerns the gene BCL2 and plasma cell neoplasm.